News October 8th, 2025 TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immunooncology and metastatic prevention oncology company January 11th, 2022 Polynoma Receives SPA Agreement from the U.S. FDA for a Pivotal Phase 3 Clinical Study of Seviprotimut-L June 23rd, 2020 Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L May 13th, 2020 Polynoma Presenting Final Analysis of MAVIS Phase III Part B1 Data of Its Investigational Melanoma Vaccine, Seviprotimut-L, at ASCO20 Virtual Scientific Program November 06th, 2019 Polynoma Presenting Interim Phase III Data for Its Investigational Melanoma Vaccine, Seviprotimut-L, at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
